Acrylamide (50 mg/kg) was daily administered intraperitoneally to normal and diabetic rats for 2 weeks. Its impact was evaluated by histopathology, western blot, and serum biochemical analysis. Levels of serum alanine aminotransferase, blood urea nitrogen, uric acid, creatinine, and lactate dehydrogenase in acrylamide-treated diabetic rats were higher than in acrylamide-treated non-diabetic rats. Also, liver and kidney tissue lesions induced by acrylamide were more severe in diabetic rats than in normal rats. The higher toxicity of acrylamide to diabetic rats may be caused by the overexpression of CYP2E1 monooxygenase, potentially resulting in the metabolic formation of the more reactive glycidamide.
No takes yet. Share an insight, caveat, or question.
Karimani et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: